先聲藥業(02096.HK)抗新冠候選藥物臨床試驗獲批准
先聲藥業(02096.HK)公布,集團與中國科學院上海藥物研究所、武漢病毒研究所合作的抗新型冠狀病毒(「SARS-CoV-2」)候選藥物SIM0417已獲得國家藥品監督管理局簽發的藥物臨床試驗批准通知書,擬用於曾暴露於新冠檢測陽性感染者的密接人群的暴露後預防治療。
在已完成的臨床前試驗中,SIM0417顯示出廣譜抗病毒活性,良好的體內藥代動力學特性和安全性,是一款高活性、低毒性、可口服的小分子抗SARS-CoV-2候選藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.